GERMANY: SCHERING IN CONTRAST AGENT DEAL

Article Abstract:

Schering AG is taking a stake worth US$ 20mn in Epix Medical Inc. of Cambridge, Massachusetts, and paying another US$ 30mn for the further development and marketing rights of MS-325, a NMR contrast agent for cardiovascular imaging. The rights cover all countries except for Japan. Moreover, the German company has secured rights to a further cardiovascular contrast agent of Epix. On the other hand, Epix gets an option for the further development and co-marketing of two products under development at Schering. MS-325, which is in phase III clinical trials, will be produced by Mallinckrodt Inc.

Financial management, Medical Instruments and Supplies, Medical Equipment and Supplies Manufacturing, Cardiovascular Diagnostic Equip, Schering AG, Schering Corp., Diagnostic equipment (Medical), Cardiovascular equipment, EPIX Medical Inc., Mallinckrodt Inc., EPIX

---

GERMANY/US: GRAPHICAL FILMS BY NESCHEN, GBC

Article Abstract:

Neschen AG of Buckeberg and General Binding Corporation of the US have set up a 50:50 joint venture to produce self-adhesive products for the graphical industry. In order to cover the entire ink-jet market, the new company will specialise in the production of coating widths of more than 80 inches. Marketing of the products will take place independently by the two partners in Europe and North America.

Plastic Film, Unsupported Plastics Film, Sheet, and Bag Manufacturing, Miscellaneous Plastics Products, NEC, Plastic films, General Binding Corp., GBND, Neschen AG

---

GERMANY/SWITZERLAND: WAGNER AUTOMOBIL TO EMS

Article Abstract:

J. Wagner GmbH of Markdorf, Germany, has sold its Wagner Automobilsysteme division to Ems-Chemie Holding AG of Switzerland with effect from 1 February 2001. The German unit will be integrated with Eftec Europa Holding AG of Zug, Switzerland, a systems supplier for gluing, protection and sealing in the automotive sector.

Asset sales & divestitures, Switzerland, EMS, J Wagner GmbH

Similar abstracts:

• Abstracts: GERMANY: CAPITAL INJECTION TO VIROFEM. GERMANY: CANCER VACCINE TO UNDERGO TRIALS. GERMANY: CANCER DIAGNOSTICS R&D BY ADNAGEN
• Abstracts: GERMANY: ATRIX CANCER DRUG BY MEDIGENE. SWITZERLAND: EUROPEAN HEADQUARTERS FOR SUGEN. SWITZERLAND/US: ROCHE, OSI IN CANCER R&D DEAL
• Abstracts: GERMANY: SUSTAINABLE TECHNOLOGIES R&D BY HENKEL. GERMANY: CHEMETALL POLYMER ADDITIVES SOLD. GERMANY: NEW E-COMMERCE SITE FOR CHEMICALS
• Abstracts: US/SWITZERLAND: ZELLER COOPERATES WITH SKB. SWITZERLAND/JAPAN: NATURAL COSMETICS BY WELEDA

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.